Thirty patients were treated for colonization or for skin and soft tissue infections caused by methicilinresistant Staphylococcus aureus. Three treatment regimens were evaluated, each progressively more aggressive. One regimen was 750 mg of ciprofloxacin twice daily for 5 days, the second regimen was 750 mg of ciprofloxacin twice daily for 10 to 14 days, and the final regimen was 750 mg of ciprofloxacin twice daily plus 300 mg of rifampin twice daily for 21 days. It appears that ciprofloxacin alone produced an initial eradication rate in at least one site in 50% of the patients, regardless of whether the treatment was for 5 or up to 14 days. All of the patients with eradication became recolonized within 1 week posttherapy. When rifampin was combined with ciprofloxacin, the eradication rate was 100% when the isolates were susceptible to both agents, and these patients remained free of methicillin-resistant S. aureus at 1-week and 1-month follow-ups.
Methicillin-resistant Staphylococcus aureus (MRSA) has recently emerged as both a colonizing organism and a pathogen among many hospitalized patients. The therapy of infections caused by this organism or the eradication of colonization is particularly difficult. None of the beta-lactam antibiotics appears to be clinically effective; chloramphenicol has not proven effective for the treatment of staphylococcal infection in the past; erythromycin therapy produced rapid emergence of resistance and treatment failures; and finally, the use of aminoglycosides has resulted in the rapid emergence of resistant small-colony variants. Bacitracin, although active against this organism, cannot be applied to the upper nares comfortably to enable eradication of the carrier state. Although vancomcyin has proven effective for treating staphylococcal infections in many body sites, this therapy is expensive. Furthermore, vancomcyin is ineffective for those body sites in which vancomycin does not penetrate well, such as the nares.
With the availability of the newer quinolone compounds, many of which show adequate to good in vitro activity against both methicillin-susceptible and methicillin-resistant staphylococci (9, 10) , enthusiasm for use of the quinolones for treatment of infection or colonization by MRSA seems justified. We therefore evaluated the effectiveness of ciprofloxacin for treatment of skin and soft tissue infections and for eradication of MRSA carriage.
MATERIALS AND METHODS
Patient population. Patients identified by the primary care physicians or infection control staff as infected or colonized with MRSA as the primary or sole pathogen were evaluated for entrance into the study. All patients were interviewed and clinically reevaluated by the principal investigator (R.H.K.E.) and informed consent was obtained prior to enrollment. Cultures of the skin structures were obtained by aspiration from the leading edge of the infection. Cultures of groin and perirectal areas were obtained by using salinesoaked cotton-tipped swabs over an area of at least 10 cm2. Cultures of the nares were obtained by one investigator by * Corresponding author.
inserting the saline-soaked cotton-tipped swabs into the nostrils for at least 3 cm and drawing them outward in a rotating motion against the walls of each nostril. Nares cultures were obtained for all patients as part of ongoing hospital surveillance and were noted when positive.
Treatment protocol. Patients were entered into one of the therapeutic regimens. Patients in the study had not received topical bacteriostatic or bactericidal agents for 48 h prior to receiving ciprofloxacin and did not for the remainder of the ciprofloxacin course and follow-up period. The patients entered early in the trials were treated orally twice daily with 750 mg of ciprofloxacin for 5 days. Cultures of sites which were initially positive were repeated on the last day of therapy and at 7 days posttherapy. When this regimen proved inadequate, newly enrolled patients were treated for a minimum of 10 days and a maximum of 14 days with 750 mg of ciprofloxacin twice daily. Cultures were obtained again at the end of therapy and at 7 days posttherapy. After the second regimen proved inadequate, a final regimen was used in which the patients were treated orally with 750 mg of ciprofloxacin plus 300 mg of rifampin twice daily. The treatment period was extended to 21 days. Cultures were at the end of therapy, at 7 days posttherapy, and at 30 days posttherapy. A body site which was culture positive for MRSA was considered infected if erythema, pain, or swelling was present at or surrounded the site or if profuse drainage was present. In the absence of these signs, the site was considered colonized by MRSA. Patients were seen twice weekly during therapy to be monitored for adverse reactions. A safety profile which included complete blood count and analyses of serum creatinine, serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, bilirubin, and urine levels was performed weekly during therapy.
Bacteriology. The specimens were heavily inoculated onto mannitol-salt, MacConkey, and tryptic soy-sheep blood agars (BBL Microbiology Systems, Cockeysville, Md.). Plates were incubated at 35°C. After 24 and 48 h of incubation, colonies of appropriate morphologies were further studied by microscopic examination and coagulase test (4-and 24-h tube tests). When more than five colonies of S. aureus were found on a specimen, a minimum of five colonies was tested for susceptibility. Bauer-Kirby disk diffusion tests were initially performed with penicillin, oxacillin, nafcillin, rifampin, and ciprofloxacin. The zone sizes of inhibition for ciprofloxacin were recorded. The isolates were later tested by the broth microdilution technique in Mueller-Hinton broth (3). Susceptibility or resistance was interpreted according to National Committee for Clinical Laboratory Standards guidelines (6) .
RESULTS
Clinical response. All of the 30 patients infected with MRSA clinically responded, regardless of the therapeutic regimen used. In the case of skin ulcers, the exudates became less, the erythema decreased, and the sizes of the ulcers frequently decreased. In cases of wound infections, all responded with healing and crusting by day 5 of therapy. In the four patients with MRSA colonization in the sputum, no noticeable changes in the clinical respiratory status of the patients were noted. Similarly, those patients with MRSA colonization at other sites showed no clinical change at the colonization sites during therapy.
Bacteriological response. Results of the three therapeutic regimens are shown in Table 1 . Despite the consistently good clinical outcome obtained, ciprofloxacin was able to eradicate MRSA in at least one site from only 50% of the patients. This 50% eradication occurred regardless of whether the patient was treated for 5 days or for longer periods of up to 14 days. In the 16 patients treated with ciprofloxacin alone for 5 days, 7 of 14 (50%) infected sites showed eradication of MRSA and 0 of 3 (0%) of the nares colonization sites showed eradication of this organism. In the eight patients treated with ciprofloxacin alone for 10 to 14 days, three of six (50%) of the infected sites showed eradication and zero of three nares colonization sites showed eradication of MRSA. All sites in which MRSA had been eradicated became culture positive within 1 week after termination of therapy. However, more-dramatic results were seen in the patients treated with ciprofloxacin plus rifampin. In all five (100%) patients who had isolates susceptible to both agents, MRSA strains were eradicated. Unlike the patients treated with ciprofloxacin, these patients (100%) remained culture negative at 1-month follow-up. One patient in the group given ciprofloxacin plus rifampin had an initial isolate resistant to rifampin. In this patient, the isolate was not eradicated by ciprofioxacin, which corresponds to data for the first two regimens. Additional pathogens isolated included Providencia stuartii (ulcer), Klebsiella pneumoniae (ulcer), Pseudomonas aeruginosa (wound), P. aeruginosa plus Proteus mirabilis (wound), coagulase-negative staphylococci plus Proteus mirabilis (stye), and Enterococcus sp. (wound). All of these isolates were susceptible to ciprofloxacin and were not recovered after termination of therapy. In five of these six patients, MRSA was eradicated during therapy.
A summary of the efficacy of the three therapeutic regimens is shown in Table 2 . Data are divided into infected sites versus colonized sites. For the ciprofloxacin regimens of 5 and 10 to 14 days, ciprofloxacin was more effective in eradicating MRSA from infected (50%) than colonized (25%) sites. Persistent eradication was not obtained even in the 10-to 14-day regimen. A marked improvement in both initial (100%) and persistent (100%) eradication was seen when the combination of ciprofloxacin plus rifampin was used for both infected and colonized sites. ,ug/ml, respectively. The patient treated with ciprofloxacin plus rifampin had an initial isolate resistant to rifampin and susceptible to ciprofloxacin (0.5 jig/ml). The range and MICs for 90% of the strains tested for the follow-up isolates reflect these isolates, while the MIC for 50% of the strains tested remained unchanged throughout the study.
Safety profile. All patients tolerated ciprofloxacin and rifampin well. One patient complained of a metallic taste in the mouth during therapy. No patients developed measurements of liver enzymes higher than twice normal during therapy with ciprofloxacin alone or combined with rifampin.
DISCUSSION
Ciprofloxacin is the first of the new quinolone antimicrobial agents which can be considered for treatment of skin and soft tissue infections because it maintains adequate levels in blood and tissue of most organs (1, 2) . Because of its established in vitro activity for gram-positive organisms (11) , it appeared logical to use this agent to treat infections caused by MRSA or to eradicate the carrier state involving MRSA.
All study patients responded clinically. Skin infections were either resolved or considerably reduced. The clinical responses seen in these patients is comparable to that reported by Self et al. (8) in which 21 of 22 patients having skin and skin structure infections involving S. aureus improved with ciprofloxacin therapy. In our study, MRSA was eradicated in only 50% of the cases when ciprofloxacin was used alone. This may suggest that in areas of good blood supply, tissue levels of ciprofloxacin were probably adequate to halt the infection. Indeed, concentrations as high as 4.0 ,ug/ml have been achieved with an oral 750-mg dose (4). However, as the infection resolves, the organisms residing on or colonizing the poorly vascularized epidermis remain uninhibited. An alternate explanation for the good clinical but only modest bacteriological response is that the staphylococcal infections may have resolved spontaneously and the salutary course was independent of the administered therapy.
Respiratory secretions containing MRSA were easily cleared of this organism, as demonstrated by eradication in all four cases, in one case with only 5 days of therapy. However, nares colonization with MRSA is notoriously (7), but proved inadequate for the less susceptible organisms, such as MRSA. This is best illustrated clinically by an earlier study using ciprofloxacin to treat MRSA nasal colonization in which short courses of therapy were also inadequate and which reported that long courses possibly suppressed MRSA, although the potential for recolonization posttherapy was high (5).
The regimen of 21-day therapy with ciprofloxacin plus rifampin dramatically improved the bacteriological results. The improved eradication rate may be ascribed to the longer period of ciprofloxacin treatment, but extending therapy from 5 days to 10 to 14 days of ciprofloxacin alone did little to alter the eradication rate. More likely, the improved eradication rate was due to the addition of rifampin. Rifampin is known to penetrate well not only into the skin but also into the nasal secretions. Rifampin is extraordinarily active against staphylococci, with MICs and MBCs-as low as 0.001 ,ug/ml. When combined with ciprofloxacin, it is likely that rifampin markedly increased the efficiency of MRSA eradication. One patient was treated with both ciprofloxacin and rifampin for 3 weeks, although the organism proved resistant to rifampin initially, and no eradication was achieved. When this case was excluded from analysis, the combination of ciprofloxacin plus rifampin achieved and maintained MRSA eradication in all five patients treated.
The combination of rifampin plus ciprofloxacin for susceptible isolates produced eradication rates superior to those for ciprofloxacin alone. Currently, this regimen appears useful in the management of patients colonized by or superficially infected with MRSA. Whether the development of rifampin resistance with widespread use of this regimen will vitiate its effectiveness remains to be seen.
